{"filings":[{"id":2105722,"accession_number":"0001640266-26-000007","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2026-08-06T20:03:23+00:00","items":["2.02","9.01"],"status":"ready","headline":"Voyager Q2 net loss narrows to $24.5M; cash $148.8M, runway into 2028; tau programs on track for Q4 data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $24.5M in Q2 2026 vs $33.4M in Q2 2025; collaboration revenue $3.2M (down from $5.2M).","Cash, equivalents, and marketable securities $148.8M as of June 30, 2026; expected to fund operations into 2028.","VY7523 tau PET imaging data expected Q4 2026; VY1706 tau gene therapy IND cleared, dosing expected Q4 2026.","Neurocrine partner intends to initiate NBIB-223 trial for Friedreich's ataxia in H2 2026 pending FDA IND clearance.","R&D expenses $22.0M (down from $31.3M) and G&A $7.5M (down from $10.5M) due to prioritization and restructuring."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":5758000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1592596,"accession_number":"0001104659-26-082906","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2026-07-13T12:44:19+00:00","items":["8.01"],"status":"ready","headline":"Voyager presents positive GLP tox data for tau gene therapy VY1706; plans H2 2026 dosing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["GLP toxicology data for VY1706 showed favorable tolerability in NHPs with no adverse CNS or peripheral findings up to 5x10^13 vg/kg.","Single IV dose achieved up to 75% lowering of MAPT mRNA and tau protein in key AD brain regions through six months.","ALPL brain vasculature receptor mediated VY1706 blood-brain barrier transport, supporting cross-species translatability.","IND clearance received June 2026; multi-site open-label dose-escalation trial to begin dosing in H2 2026.","Data presented at Alzheimer's Association International Conference on July 13, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":972680,"accession_number":"0001104659-26-072324","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2026-06-10T20:05:35+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Voyager shareholders approve doubling authorized shares to 245M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized capital stock increased from 125M to 245M; common stock from 120M to 240M, effective June 9, 2026.","Shareholders elected James Geraghty, Steven Hyman, and Alfred Sandrock as Class II directors until 2029.","Ratified Ernst & Young as independent auditor for fiscal year ending December 31, 2026.","Advisory vote on executive compensation approved with 32M for, 910K against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":759721,"accession_number":"0001104659-26-068591","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2026-06-01T12:00:26+00:00","items":["8.01"],"status":"ready","headline":"FDA clears IND for VY1706, Voyager's tau-silencing gene therapy for Alzheimer's","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["VY1706 targets intra- and extracellular tau; IND cleared by FDA on June 1, 2026.","Phase 1 open-label, dose-escalation trial expected to begin dosing in H2 2026.","Trial to enroll up to 18 early AD patients across 3 cohorts; highest dose 5 x 10^13 vg/kg.","Primary endpoint: safety/tolerability; secondary endpoints: CSF tau biomarkers and tau PET imaging.","Company plans to initiate multi-site study; VY1706 administered as one-time IV dose."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94311,"accession_number":"0001104659-26-057115","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Voyager Q1 net loss $27.9M, cash $172M into 2028; VY1706 tau gene therapy on track for H2 dosing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $27.9M (Q1 2026) vs $31.0M (Q1 2025); revenue $2.6M down from $6.5M due to lower collaboration revenue.","Cash, equivalents and marketable securities $171.7M; runway expected into 2028.","VY1706 tau silencing gene therapy: IND-enabling GLP tox completed; FDA IND on track for Q2, first-in-human dosing H2 2026.","VY7523 anti-tau antibody: tau PET imaging efficacy data from MAD trial expected H2 2026.","Neurocrine's NBIB-'223 for Friedreich's ataxia: GLP tox completed, FDA orphan drug designation; clinical trial H2 2026 pending IND."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":2593000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94310,"accession_number":"0001104659-26-045997","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2026-04-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Voyager Therapeutics CFO Nathan Jorgensen resigns; Robin Swartz named PFO, Amy Quinlan PAO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Nathan Jorgensen, Ph.D. resigns effective May 8, 2026, to pursue new opportunity; no disagreement with company.","Board appoints Robin Swartz (COO/CBO) as principal financial officer and treasurer effective May 8, 2026.","Board appoints Amy Quinlan (VP Finance) as principal accounting officer effective May 8, 2026.","Swartz previously served as interim PFO and PAO in 2024; Quinlan joined in Jan 2025 from Vor Biopharma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106577,"accession_number":"0001104659-26-025201","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Voyager Q4 2025 net loss $27.4M, cash $201.7M; key pipeline milestones H2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net loss $27.4M vs $34.5M in Q4 2024; full year net loss $119.7M vs $65.0M.","Collaboration revenue Q4 $15.3M (up 143% YoY) but full year $40.4M (down 50% YoY).","Cash $201.7M at Dec 31 2025; runway expected into 2028 with up to $2.4B in milestone potential.","VY1706 (tau-silencing) IND planned Q2 2026, first-in-human dosing H2 2026; VY7523 tau PET data H2 2026.","APOE gene therapy program paused; Neurocrine milestone $3M triggered in Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106576,"accession_number":"0001104659-26-013897","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Chief Medical Officer Toby Ferguson resigns; CEO Sandrock takes over clinical leadership","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Toby Ferguson, M.D., Ph.D., resigned as CMO effective Feb 20, 2026, to pursue a new opportunity.","Resignation is not due to any disagreement with the company.","CEO Alfred W. Sandrock, Jr., M.D., Ph.D., will assume interim oversight of clinical development programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106575,"accession_number":"0001104659-26-001955","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Voyager Therapeutics outlines pivotal 2026 milestones: tau programs, capsid validation, NeuroShuttle data","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Biogen's BIIB080 Phase II data expected mid-2026; Voyager's VY1706 gene therapy first-in-human in H2 2026.","VY7523 anti-tau antibody trial fully enrolled; tau PET imaging data expected H2 2026.","Neurocrine plans to initiate clinical trial with NBIB-‘223 for Friedreich's ataxia in 2026.","ALPL-NeuroShuttle shows similar target engagement to TfR shuttle with more sustained brain exposure; partnering interest strong.","Four wholly owned and partnered IV-delivered neuro gene therapy programs advanced to preclinical toxicology."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122908,"accession_number":"0001104659-25-108841","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Voyager Q3 net loss widens to $27.9M; cash runway into 2028; NeuroShuttle platform launched","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $27.9M (vs $9.0M in Q3 2024); collaboration revenue fell to $13.4M from $24.6M.","Cash, equivalents, marketable securities $229M; runway extended into 2028.","New collaboration with Transition Bio for TDP-43 small molecules (ALS/FTD); upfront single-digit million, milestones up to $500M.","Introduced ALPL-VYGR-NeuroShuttle nonviral platform; murine data shows >3 weeks brain expression.","Novartis discontinues two discovery programs (rights return); Neurocrine milestone $3M expected Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":25038000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139606,"accession_number":"0001104659-25-085977","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Voyager Therapeutics presents at Citi Biopharma Conference; no specific updates disclosed in filing excerpt","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company presented at Citi's 2025 Biopharma Back to School Conference on September 2, 2025.","Presentation titled 'Leveraging Genetics to Treat Neurological Diseases' focuses on genetic approaches.","No financial results, pipeline milestones, or guidance changes are identifiable from the provided excerpt.","The filing does not contain material new information beyond the fact of the presentation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139605,"accession_number":"0001558370-25-010507","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Voyager Q2 net loss widens to $33.4M; cash runway extended into 2028","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $33.4M in Q2 2025 vs $10.1M in Q2 2024; collaboration revenue fell to $5.2M from $29.6M.","Cash and marketable securities $262M; runway extended into 2028, enabling multiple clinical data readouts.","Added wholly-owned APOE program to Alzheimer's pipeline, fourth asset in franchise; tau PET data for VY7523 expected H2 2026.","Neurocrine-partnered FA and GBA1 gene therapy programs expected to enter clinical trials in 2026 after IND submissions in 2025.","Potential for $2.6B in development milestone payments from 11 partnered programs, including up to $35M from GBA and FA programs."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":11673000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157187,"accession_number":"0001104659-25-056835","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Voyager stockholders approve 2025 stock plans, elect directors at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Approved 2025 Stock Incentive Plan: 28.6M for, 11.3M against, 8.5M broker non-votes.","Approved Amended and Restated 2015 ESPP: 36.5M for, 3.3M against, 8.5M broker non-votes.","Elected Class I directors Colón, Mackey, Pierce, Scangos; Scangos had 6.7M votes withheld.","Ratified Ernst & Young as FY2025 auditor: 48.1M for, 0.25M against.","Say-on-pay approved: 37.8M for, 2.0M against, 0.1M abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157186,"accession_number":"0001558370-25-006482","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Voyager Q1 2025 net loss $31.0M, revenue down 67% YoY; cash $295M into mid-2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $31.0M vs $11.3M YoY; collaboration revenue $6.5M vs $19.5M YoY (−67%).","Cash, cash equivalents & marketable securities $295M; expects runway into mid-2027.","R&D expenses $31.5M (+16% YoY); G&A $9.6M (+12% YoY).","VY1706 tau silencing gene therapy achieved up to 73% tau mRNA knockdown in NHPs; IND/CTA filings expected 2026.","Neurocrine-partnered FA and GBA1 IND submissions on track for 2025; up to $35M milestone potential 2025-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":6473000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175534,"accession_number":"0001558370-25-002702","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Voyager Therapeutics Q4 2024 net loss $34.5M; tau gene therapy VY1706 IND filing planned for 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $34.5M in Q4 2024 vs net income $56.4M in Q4 2023; full year net loss $65.0M vs income $132.3M.","Collaboration revenue $6.3M in Q4 2024 vs $90.1M in Q4 2023; $80.0M full year vs $250.0M in 2023.","Cash and marketable securities $332.4M as of Dec 31, 2024; runway extended into mid-2027 excluding milestones.","Tau silencing gene therapy VY1706 reduced tau mRNA 50-73% in NHP study; IND filing anticipated in 2026.","Anti-tau antibody VY7523 MAD study initiated; initial tau PET data in Alzheimer's patients expected H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175533,"accession_number":"0001104659-25-011155","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2025-02-11T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Voyager delays SOD1 ALS IND filing; switches payload after NHP data; cash runway to mid-2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["VY9323 IND/CTA filing no longer expected mid-2025 due to need for alternate payload after 3-month NHP data.","Capsid unchanged; decision based on achieving desired product profile for SOD1 ALS gene therapy.","Other programs unaffected: Neurocrine GBA1 and Friedreich’s ataxia IND filings still on track for 2025.","Tau silencing program VY1706 IND expected in 2026; preclinical activity levels achieved.","Cash and equivalents plus collaboration reimbursements fund operations into mid-2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192488,"accession_number":"0001558370-24-015299","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Voyager Q3 net loss narrows to $9.0M; new Novartis capsid license; VY7523 SAD data H1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 collaboration revenue $24.6M (up from $4.6M YoY); net loss $9.0M vs $25.9M.","Licensed TRACER capsid to Novartis for undisclosed rare neurologic target; $15M upfront, up to $305M milestones.","Neurocrine partnership selected 3rd development candidate, triggering $3M milestone.","VY7523 anti-tau antibody SAD trial enrollment complete; top-line safety/PK data expected H1 2025.","Cash $345.4M at Sep 30; plus $18M received in Oct; runway into 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":73723000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208959,"accession_number":"0001104659-24-097152","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2024-09-05T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Voyager grants Novartis license to capsid for gene therapy; $15M upfront, up to $305M milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Novartis receives exclusive license to a capsid from Voyager's TRACER platform for a single gene target.","One-time $15M fee paid upfront; Voyager eligible for $130M in development/regulatory/commercial milestones.","Additional sales milestones up to $175M per product plus tiered mid- to high-single-digit royalties.","Novartis' prior option rights for other targets expired as of September 3, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208958,"accession_number":"0001558370-24-011071","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Voyager Q2 net loss narrows to $10.1M; cash $371M; anti-tau trial underway, data H1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 collaboration revenue $29.6M (vs $4.9M YoY); net loss $10.1M vs $22.2M loss a year earlier.","Cash, equivalents and marketable securities at $371M as of June 30; runway into 2027.","First participants dosed in Phase 1a SAD of anti-tau antibody VY7523; top-line safety/PK data expected H1 2025.","Three gene therapy INDs on track for 2025: SOD1 ALS (VY9323), GBA1, and Friedreich's ataxia.","Appointed Nathan Jorgensen as CFO; received $3M milestone from Neurocrine for GBA1 candidate selection."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":49094000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226784,"accession_number":"0001104659-24-071048","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Voyager Therapeutics appoints Nathan Jorgensen as CFO effective July 8, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jorgensen, 47, previously CFO of Vor Biopharma; will report to CEO Alfred Sandrock.","Annual base salary of $480,000; target annual bonus of 40% of base salary.","Inducement equity grants: option to purchase 200,000 shares (4-year vest) and RSU for 80,000 shares (3-year vest).","Severance: 12 months base salary plus pro-rata bonus and COBRA on termination without cause or for good reason within 12 months of a sale event.","Employment at-will; standard non-compete and non-solicitation provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226783,"accession_number":"0001104659-24-069063","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Voyager stockholders elect three Class III directors, approve say-on-pay, ratify auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Michael Higgins, Jude Onyia, and Nancy Vitale elected Class III directors until 2027.","Non-binding advisory vote on executive compensation passed with 35.9M for vs 1.7M against.","Ratification of Ernst & Young as independent auditor for FY2024 with 46.3M for, 72K against.","Broker non-votes of 8.6M on director elections and say-on-pay; none on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226782,"accession_number":"0001104659-24-062257","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2024-05-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Voyager Therapeutics doses first participants in Phase 1a trial of anti-tau antibody VY-TAU01 for Alzheimer's","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First participants dosed in Phase 1a SAD trial of VY-TAU01, an anti-tau antibody for Alzheimer's disease.","Trial is randomized, double-blind, placebo-controlled, evaluating safety and PK in healthy adult volunteers.","Study conducted at a single U.S. site; expected to enroll approximately 48 patients across multiple cohorts.","VY-TAU01 designed to inhibit spread of pathological tau in Alzheimer's disease."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226781,"accession_number":"0001558370-24-007951","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Voyager Q1 net loss $11.3M; IND cleared for VY-TAU01; cash $400M to 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $11.3M vs net income of $124.0M in Q1 2023; collaboration revenue $19.5M down from $150.5M.","Cash, equivalents and marketable securities of $400.5M as of March 31, 2024; runway into 2027.","IND clearance from FDA for anti-tau antibody VY-TAU01 for Alzheimer's disease; Phase 1a dosing imminent.","Development candidates selected in GBA1 and Friedreich's Ataxia gene therapy programs with Neurocrine; $8M total milestones triggered.","Appointed Toby Ferguson, M.D., Ph.D., as Chief Medical Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":19516000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226780,"accession_number":"0001104659-24-042502","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2024-04-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Voyager Therapeutics CFO Peter Pfreundschuh to resign; Robin Swartz appointed as principal financial officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Peter Pfreundschuh resigns effective April 12, 2024; remains as Senior Financial Advisor until May 5, 2024.","Robin Swartz, current COO, appointed principal financial and accounting officer effective April 12.","Pfreundschuh receives salary continuation for 12 months, prorated 2024 bonus, and health insurance.","Unvested equity awards continue to vest during consulting period up to ~July 2024.","Separation Agreement includes release of claims and non-disparagement obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245744,"accession_number":"0001104659-24-033726","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2024-03-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Voyager Therapeutics names Toby Ferguson as Chief Medical Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Employment starts March 25, 2024; base salary $485,000, target bonus 40%.","Granted inducement option for 210k shares and RSU for 105k shares, both time-vesting.","Dr. Ferguson previously VP, Head of Neuromuscular Development at Biogen (2013-2024).","Severance provides 12 months base salary and pro-rata bonus if terminated without cause or for good reason within 12 months post sale event.","At-will employment; standard non-compete and confidentiality obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245743,"accession_number":"0001558370-24-001987","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Voyager Therapeutics reports Q4 net income $56.4M, pro-forma cash $431M, pipeline milestones","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 collaboration revenue $90.1M (vs -$1.6M YoY), net income $56.4M (vs loss $23.6M).","FY 2023 collaboration revenue $250.0M (vs $40.9M), net income $132.3M (vs loss $46.4M).","Pro-forma cash $431M after Novartis $100M and Jan 2024 $100M public offering; runway into 2027.","Selected development candidates: SOD1 ALS gene therapy (IND mid-2025) and Friedreich's ataxia (triggered $5M milestone, clinic 2025).","Novartis collaboration: $80M upfront + $20M equity, up to $1.2B milestones; VY-TAU01 IND expected H1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":2.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":250008000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245742,"accession_number":"0001104659-24-002271","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Voyager Therapeutics prices $100M public offering; closes $20M Novartis private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Public offering of 7,777,778 shares at $9.00/share and 3,333,333 pre-funded warrants at $8.999, gross proceeds ~$100M.","Underwriters have 30-day option to purchase up to 1,666,665 additional shares at $9.00/share.","Net proceeds estimated ~$93.5M (up to ~$107.6M if option exercised) to fund AD and ALS programs and working capital.","Novartis private placement closed Jan 3, 2024: 2,145,002 shares at $9.324/share for ~$20M.","Company expects cash runway into 2027 using existing cash, collaboration reimbursements, and Novartis upfront."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245741,"accession_number":"0001104659-24-000084","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2024-01-02T23:59:59+00:00","items":["1.01","2.02","3.02","8.01"],"status":"ready","headline":"Voyager Therapeutics enters $100M upfront collaboration with Novartis for SMA and HD gene therapy","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Voyager Therapeutics entered into a license and collaboration agreement with Novartis for AAV capsids for SMA and Huntington's disease programs, with $80M upfront payment and $20M stock purchase.","Voyager eligible for up to $200M in milestones for SMA program and $225M for HD program, plus sales milestones and tiered royalties.","Voyager estimates preliminary cash of $230.7M as of Dec 31, 2023; adjusted to $330.7M after anticipated $100M upfront from Novartis.","Voyager plans to submit IND for VY-TAU01 (Alzheimer's) in first half 2024 and for SOD1 ALS gene therapy in mid-2025.","Voyager entered into a stock purchase agreement and investor agreement with Novartis, including standstill and lock-up restrictions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263212,"accession_number":"0001104659-23-123809","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2023-12-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Voyager selects lead candidate for SOD1-ALS gene therapy; IND filing expected mid-2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lead candidate combines siRNA construct with IV-delivered TRACER capsid targeting SOD1-mutated ALS.","Non-human primate study showed 73% reduction of SOD1 in cervical spinal cord motor neurons after single IV dose.","Another preclinical candidate previously increased survival by median 152 days in G93A mouse model.","Additional candidate data to be presented at upcoming scientific conference."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263211,"accession_number":"0001558370-23-017753","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Voyager Q3 net loss $25.9M; advances VY-TAU01 IND, SOD1 ALS candidate selection by year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $25.9M in Q3 2023 vs net income $17.6M in Q3 2022; collaboration revenue fell to $4.6M from $41.1M.","Cash, equivalents and marketable securities $252.9M as of Sep 30, 2023; runway expected into mid-2025.","Initiated GLP tox for anti-tau antibody VY-TAU01; IND filing expected H1 2024 for Alzheimer's disease.","SOD1 ALS gene therapy program on track for development candidate selection in 2023, IND target mid-2025.","License of TRACER capsid from Pfizer to Alexion/AstraZeneca Rare Disease assigned; terms unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":1.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":159947000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280402,"accession_number":"0001104659-23-092566","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2023-08-16T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Voyager Therapeutics expands leased space by ~61k SF; annual rent ~$4.9M starting June 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Total leased premises grows to 93,449 rentable SF (from ~32k SF) with addition of third floor.","Expansion rent commences June 2024 at $4,873,906.50 annual base rent, escalating ~3% annually through Jan 2031.","Landlord provides up to $1,839,210 tenant improvement allowance; tenant covers excess costs.","Security deposit letter of credit increased from ~$1.04M to ~$2.26M as of Jan 1, 2024.","Parking allocated to tenant increases from 75 to 228 spaces upon expansion commencement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280401,"accession_number":"0001558370-23-013047","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Voyager Q2 net loss $22.2M, launches anti-Aβ gene therapy for Alzheimer's","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2023 collaboration revenue $4.9M (up from $0.7M YoY); net loss $22.2M vs $19.1M YoY.","Cash, equivalents and marketable securities $272.7M as of June 30, 2023; funding into 2025.","New vectorized anti-Aβ antibody gene therapy research initiative for Alzheimer's disease launched.","Executed license agreement with Sangamo for prion disease treatment using TRACER capsid.","VY-TAU01 anti-tau antibody IND on track for H1 2024; GLP tox studies to start in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":2.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":155333000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280400,"accession_number":"0001104659-23-079340","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2023-07-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Voyager Therapeutics appoints Jacquelyn Fahey Sandell as Chief Legal Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jacquelyn Fahey Sandell named CLO effective July 10, 2023; reports to CEO Alfred Sandrock.","Base salary of $450,000 per year; eligible for annual cash bonus at 40% of base salary target.","Inducement equity grant: option to purchase 122,000 shares (4-year vest) and RSU for 61,000 shares (3-year vest).","Severance includes 12 months base salary, pro-rata target bonus, COBRA subsidy, and full equity acceleration upon qualifying termination within 12 months of a sale event."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298952,"accession_number":"0001104659-23-068910","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2023-06-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Voyager Therapeutics stockholders elect three Class II directors at 2023 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Class II directors: Steven Hyman (20,552,674 for), James A. Geraghty (16,613,243 for), Alfred Sandrock (20,551,414 for); broker non-votes 8,405,461.","Non-binding advisory say-on-pay approved with 20,162,995 for, 523,972 against, 33,553 abstain, and 8,405,461 broker non-votes.","Ratified Ernst & Young as independent auditor for fiscal 2023 with 29,090,596 for, 32,521 against, 2,864 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298951,"accession_number":"0001558370-23-008652","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Voyager Therapeutics Q1 net income $124M on $150.5M collaboration revenue; cash $273.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $124.0M in Q1 2023 vs net loss of $21.3M in Q1 2022; collaboration revenue $150.5M (vs $0.7M).","Cash, cash equivalents and marketable securities $273.3M as of March 31, 2023; plus $25M Novartis option payment received after quarter.","Neurocrine Biosciences strategic collaboration: $175M upfront, up to $1.5B development milestones, $2.7B commercial milestones.","Novartis exercised options for novel TRACER capsids: $25M payment, up to $600M milestones and royalties.","Anti-tau antibody program VY-TAU01; IND filing on track for H1 2024. SOD1 program lead candidate now expected H2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":2.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":150480000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298950,"accession_number":"0001104659-23-057461","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Voyager Therapeutics appoints George Scangos to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["George Scangos, Ph.D., appointed as Class I director effective May 9, 2023, serving until 2025 annual meeting.","Scangos will serve on the Science and Technology Committee of the Board.","Compensation includes $40,000 annual cash retainer and initial option for 44,000 shares vesting over 4 years.","Scangos brings experience as former CEO of Biogen, Vir Biotechnology, and Exelixis.","He will enter standard indemnification agreement with Voyager."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319124,"accession_number":"0001104659-23-031428","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Voyager Therapeutics has less than $2M at Silicon Valley Bank, less than 1% of total cash","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Aggregate SVB accounts balance less than $2M, under 1% of total cash, equivalents and marketable securities.","Substantially all cash and securities held at institutions other than SVB.","SVB depositors have access to all funds starting March 13, 2023 per joint regulatory statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319123,"accession_number":"0001558370-23-002988","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2023-03-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Voyager reports Q4 2022 net loss of $23.6M; highlights partnerships with Neurocrine, Novartis, Pfizer","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 net loss $23.6M vs $5.7M income in Q4 2021; full-year net loss $46.4M vs $71.2M loss in 2021.","Neurocrine collaboration closed Jan 2023: $175M upfront, up to $4.2B milestones, plus royalties and opt-in for GBA1 program.","Novartis exercised capsid license options for two CNS targets (March 2023): $25M payment, up to $600M milestones plus royalties.","Pfizer exercised capsid option in Oct 2022: $10M payment, up to $290M milestones plus royalties.","Cash $118.8M at Dec 31, 2022; expected into 2025 after deals. Pipeline: VY-TAU01 selected, SOD1 candidate in H1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319122,"accession_number":"0001104659-23-024939","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2023-02-24T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Voyager closes Neurocrine collaboration, receives $175M; Neurocrine CSO joins board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Collaboration Agreement effective; Neurocrine pays $136M upfront.","Neurocrine buys 4,395,588 shares at $8.88/share for ~$39M.","Jude Onyia, Ph.D., Neurocrine's CSO, appointed to board effective closing.","Onyia designated Class III director until 2024 annual meeting; Neurocrine retains nomination right while holding ≥10%.","Onyia receives standard non-employee director compensation: $40K cash retainer, initial option for 44,000 shares, annual option for 22,000 shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319121,"accession_number":"0001104659-23-024436","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2023-02-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Voyager Therapeutics SVP & General Counsel Robert Hesslein to depart April 28, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert Hesslein resigns as SVP and General Counsel effective April 28, 2023; transition period until then.","Severance includes 12 months salary continuation, prorated 2023 bonus ($180,302 target), and COBRA premium payments for 12 months.","Post-separation consulting agreement through Sept 30, 2023; unvested RSUs and stock options continue vesting during consulting term.","Hesslein signs release of claims, reaffirms confidentiality and non-solicitation obligations, and agrees to non-disparagement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319120,"accession_number":"0001104659-23-002047","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["1.01","2.02","3.02","8.01"],"status":"ready","headline":"Voyager Therapeutics Enters Gene Therapy Collaboration with Neurocrine for Up to $1.96B in Milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Neurocrine pays Voyager $136M upfront (net of $39M stock purchase) for GBA1 and three CNS gene therapy programs.","Voyager eligible for up to $985M in development milestones for GBA1 and up to $175M per New Discovery Program.","Commercial milestones up to $950M per GBA1 product and $275M per New Discovery product; tiered royalties also apply.","Neurocrine purchases 4,395,588 shares of Voyager common stock at $8.88/share (~$39M) under a separate stock purchase agreement.","Voyager shifts Huntington's disease program to vectorized siRNA approach using proprietary TRACER capsids."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337352,"accession_number":"0001104659-22-126797","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2022-12-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Voyager Therapeutics appoints Grace E. Colón, Ph.D. to board of directors, effective Jan 1, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Grace E. Colón appointed as Class I director; term runs until 2025 annual meeting.","Annual cash retainer of $40,000 for board service; $6,000 for Compensation Committee membership.","Initial option grant of 44,000 shares vesting quarterly over four years; annual option of 22,000 shares thereafter.","Dr. Colón also serves as Executive Chair of ProterixBio and director of CareDx; no family relationships with officers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337351,"accession_number":"0001558370-22-016731","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Voyager Therapeutics reports Q3 net income $17.6M; Pfizer exercises TRACER capsid option","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Collaboration revenue $41.1M (vs $1.5M YoY) driven by $40M Pfizer option exercise recognition.","Net income $17.6M vs loss of $25.1M; cash $131.6M plus $10M Pfizer payment received in October.","Pfizer exercised option to license novel capsid; $10M payment, up to $290M in milestones plus tiered royalties.","Pipeline: lead development candidates for GBA1, SOD1, anti-tau programs expected Q4 2022 to H1 2023.","Novartis option decision on TRACER capsids for up to 5 targets expected by March 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":42457000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337350,"accession_number":"0001104659-22-105560","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2022-10-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Pfizer exercises option on Voyager TRACER capsid for rare CNS disease; $10M fee","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pfizer exercised License Option for Voyager's novel capsid for an undisclosed rare neurologic CNS disease gene therapy program.","Voyager receives $10M upfront fee and is eligible for future development, regulatory and sales milestone payments plus royalties.","Pfizer did not exercise option for cardiovascular target; rights for that target revert to Voyager.","Option follows prior agreement from Oct 2021 under which Pfizer evaluated Capsids through Sept 30, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354718,"accession_number":"0001104659-22-098047","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2022-09-07T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Voyager Therapeutics appoints new CFO, CSO, and SVP of Corporate Affairs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Peter Pfreundschuh named CFO effective Sept 19, 2022; base salary $455K, target bonus 40%, 200K option + 125K RSU.","Todd Carter promoted to CSO effective Sept 19, 2022; base salary $410K, target bonus 40%, 165K option.","Trista Morrison appointed SVP of Corporate Affairs and Chief of Staff to CEO effective Sept 19, 2022.","Julie Burek remains VP of Finance; Pfreundschuh assumes principal financial and accounting officer roles.","Equity grants for Pfreundschuh are inducement awards under Nasdaq Listing Rule 5635(c)(4)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354717,"accession_number":"0001558370-22-012231","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Voyager Therapeutics prioritizes tau/GBA1/SOD1-ALS pipeline, posts Q2 net loss of $19.1M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q2 collaboration revenue $0.7M (down from $1.4M YoY); net loss $19.1M vs $30.1M in Q2 2021.","Prioritized pipeline: tau antibody for Alzheimer's, GBA1 gene therapy for Parkinson's, SOD1 gene silencing for ALS.","Identified receptor for TRACER AAV capsid; AAV9-derived capsid shows 50-60x better brain transduction vs AAV9.","Catherine J. Mackey, Ph.D. (ex-Pfizer) appointed to Board of Directors, effective Aug 15, 2022.","Cash $148.1M expected to fund operations into 2024; Pfizer option decision by Oct 2022, Novartis by Mar 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354716,"accession_number":"0001104659-22-083431","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2022-07-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Voyager Therapeutics appoints Catherine J. Mackey, Ph.D. to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Mackey appointed as Class I director effective August 15, 2022, serving until 2025 annual meeting.","She joins the Audit Committee and Science and Technology Committee.","Annual cash retainers: $40,000 for Board, $8,000 for Audit, $5,000 for Science & Technology.","Receives initial option for 44,000 shares vesting quarterly over 4 years; annual option for 22,000 shares thereafter.","Dr. Mackey previously was SVP at Pfizer and serves on other biotech boards (IDEAYA, Avid Bioservices, Cour Pharmaceuticals)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372721,"accession_number":"0001104659-22-073892","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2022-06-23T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Voyager Therapeutics terminates Cambridge lease and BioNTech sublease without penalty","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease termination effective June 22, 2022; no termination fees incurred.","Original lease on ~45,000 sq ft at 75 Sidney Street was set to expire Nov 30, 2026.","BioNTech sublease on ~18,000 sq ft terminated early; BioNTech enters direct lease with landlord.","Voyager conveyed certain personal property in the premises to BioNTech via bill of sale.","Both lease and sublease ended without any penalty; no further rent obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372720,"accession_number":"0001104659-22-068958","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2022-06-07T23:59:59+00:00","items":["5.02","5.07","8.01","9.01"],"status":"ready","headline":"Voyager Therapeutics interim CSO Glenn Pierce resigns as planned, enters consulting agreement; shareholders re-elect him","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Glenn Pierce resigned as Interim CSO effective June 2, 2022, after serving in the role since June 2021 on a part-time basis.","On June 6, Pierce signed a consulting agreement with Voyager capped at $120,000, valid until June 5, 2023, for transition services.","At the June 6 annual meeting, Pierce was re-elected as Class I director with 21,014,996 votes (88.9% of votes cast).","Shareholders approved say-on-pay with 23,447,480 votes and ratified Ernst & Young as auditor with 30,505,725 votes.","Todd Carter, SVP Research, assumed increased R&D responsibilities starting June 3, reporting to CEO; search for a CSO is underway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372719,"accession_number":"0001558370-22-007048","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2022-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Voyager Q1 net loss $21.3M, inked Novartis deal for $54M upfront","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net loss $21.3M; collaboration revenue $0.7M (down from $6.5M YoY); cash $166.8M, runway into 2024.","Novartis license option: $54M upfront, up to $1.5B milestones for TRACER capsids on up to 5 CNS targets.","Alfred Sandrock appointed CEO (March 2022); Robin Swartz promoted to COO.","TRACER AAV9 capsid yields 50-60x better brain transduction in mice/macaques vs AAV9; AAV5 capsid 20x vs AAV9.","Preclinical data: vectorized HER2 antibody reduces tumor burden; GBA1, SOD1, anti-tau programs advancing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":658000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-05-04T23:59:59+00:00|372719"}